Search results for "Drug Interaction"

showing 10 items of 246 documents

Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro ex…

2014

Concomitant food intake can diminish oral absorption of drugs with limited permeability and an absorption window in the proximal intestine, due to viscosity-mediated decrease in dosage form disintegration time and drug dissolution rate. Three poorly-permeable drugs (atenolol, metformin hydrochloride, and furosemide) exhibiting negative food effect, and one highly-soluble and highly-permeable (metoprolol tartrate), serving as a negative control, were selected for the study. In vitro and in silico tools were used to evaluate the influence of media viscosity on drug bioperformance under fasted and fed conditions. The obtained results demonstrated that increased medium viscosity in the presence…

Absorption (pharmacology)DrugMetoprolol Tartratemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralPharmaceutical formulationPharmacologyDosage formPermeabilityFood-Drug InteractionsPharmacokineticsPoorly-permeable drugsFurosemideHumansDissolution testingSolubilityDisintegrationmedia_commonChromatographyChemistryViscosityReproducibility of ResultsHydrogen-Ion ConcentrationFood effectMetforminAtenololIntestinal AbsorptionSolubilityFoodDissolutionAbsorption simulationEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid.

1991

In situ intestinal absorption of baclofen in the rat in the presence of beta-alanine has been investigated. Through the perfusion of 0.50 mM baclofen solutions containing variable concentrations of the aminoacid (from 5 to 100 mM), a partially competitive inhibition of baclofen absorption was characterized: absorption rate pseudoconstants of the spasmolytic drug decrease as beta-alanine concentration increases, until a limiting value is obtained (36.8 per cent of that found for baclofen alone). A computer method was developed in order to calculate parameters governing baclofen absorption in the presence of beta-aminoacid, with the following results: Vm = 11.22 mM h-1; Km = 7.42 mM; Ki = 2.4…

Absorption (pharmacology)MaleBaclofenStereochemistryPharmaceutical Sciencebeta-AlanineMichaelis–Menten kineticsIntestinal absorptionchemistry.chemical_compoundNon-competitive inhibitionPharmacokineticsIntestine SmallAnimalsPharmacology (medical)Drug InteractionsPharmacologyChromatographyWaterRats Inbred StrainsGeneral MedicineRatsDietary aminoacidBaclofenchemistryIntestinal Absorptionbeta-AlanineBiopharmaceuticsdrug disposition
researchProduct

Synthetic antioxidants: biochemical actions and interference with radiation, toxic compounds, chemical mutagens and chemical carcinogens.

1984

Abstract Biological actions of 4 commonly used synthetic antioxidants — butylated hydroxyanisole, butylated hydroxytoluene, ethoxquin and propul gallate — on the molecular, cellular and organ level are compiled. Such actions may be divided into modulation of growth, macromolecule synthesis and differentiation, modulation of immune response, interference with oxygen activation and miscellaneous. Moreover, an overview of beneficial and adverse interactions of these antioxidants with exogenous noxae is given. Beneficial interactions include radioprotection, protection against acute toxicity of chemicals, antimutagenic activity and antitumorigenic action. Possible mechanisms of the antitumorige…

AdultAntioxidantmedicine.medical_treatmentButylated HydroxyanisoleMutagenAnisolesIn Vitro TechniquesToxicologymedicine.disease_causeKidneyRadiation ToleranceAntioxidantschemistry.chemical_compoundMiceEthoxyquinGallic AcidNeoplasmsmedicineButylated hydroxytolueneAnimalsHumansDrug InteractionsPropyl GallateCarcinogenCarcinogen MetabolismKidney metabolismBiological activityButylated HydroxytolueneRatsBiochemistrychemistryLiverEnzyme InductionAntibody FormationCarcinogensQuinolinesButylated hydroxyanisoleMutagensToxicology
researchProduct

Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B

2009

Objectives To analyse the potential antagonism between azoles, which inhibit ergosterol synthesis, and polyenes, which bind directly to ergosterol in cell membranes, in patients receiving sequential azole-polyene treatment. Methods In an earlier randomized, double blind study of liposomal amphotericin as initial therapy for invasive filamentous fungal infection (IFFI), a 3 mg/kg/day dose had a favourable overall response rate of 50% and 12 week survival rate of 72%. No improved outcome was seen with 10 mg/kg/day for the first 14 days. The study population was further analysed for the effect of prior azole exposure on treatment responses to liposomal amphotericin B. The protocol allowed prio…

AdultAzolesMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentmedicine.drug_classAntibioticsPharmacologyAspergillosisGastroenterologyYoung AdultPharmacotherapyDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BmedicineHumansDrug InteractionsPharmacology (medical)ChildSurvival rateMycosisAgedPharmacologyVoriconazolechemistry.chemical_classificationbusiness.industryInfantMiddle Agedmedicine.diseaseTreatment OutcomeInfectious DiseasesMycoseschemistryChild PreschoolAzoleFemalebusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct

Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – Implications for the evaluation of …

2013

Quercetin has been shown to inhibit intestinal P-glycoprotein-mediated drug efflux. A crossover clinical study was performed in 10 healthy volunteers to assess the effect of single-dose and repeated quercetin intake on the pharmacokinetics of talinolol, a substrate of intestinal P-glycoprotein. Unexpectedly, mean area under the plasma concentration-time curve (AUC0-48h) and maximal plasma concentration (cmax) were slightly decreased following concomitant and short-term quercetin administration (3186.0 versus 2468.3 and 2527.7 ng h/ml, p>0.05; 309.7 versus 212.0 and 280.6 ng/ml, p>0.05). Individual analysis revealed that talinolol AUC0-48h was lowered by 23.9% up to 60.6% in 5 subjects and c…

AdultMaleATP Binding Cassette Transporter Subfamily BFlavonoidCmaxAdministration OralPharmaceutical SciencePharmacologyDrug Administration SchedulePropanolaminesYoung Adultchemistry.chemical_compoundPharmacokineticsHumansDrug Interactionsheterocyclic compoundsIntestinal MucosaP-glycoproteinchemistry.chemical_classificationCross-Over StudiesDose-Response Relationship DrugbiologyBiological TransportTransporterMiddle AgedHealthy VolunteersIntestineschemistrybiology.proteinFemaleQuercetinEffluxQuercetinTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.

2017

We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their…

AdultMaleAdenosineAmbrisentanAdolescent030204 cardiovascular system & hematologyPharmacologyPlaceboHypoxemia03 medical and health sciencesYoung Adult0302 clinical medicineDouble-Blind MethodmedicineHumansPharmacology (medical)Adverse effectHypoxiaExercisePharmacologyPhenylpropionatesbusiness.industryAltitudeEndothelinsResearchArticlesHypoxia (medical)Drug interactionMiddle AgedAminophylline3. Good healthPyridazinesAnesthesiaAminophyllineDrug Therapy CombinationFemalemedicine.symptomEndothelin receptorbusiness030217 neurology & neurosurgerymedicine.drugSignal TransductionClinical pharmacology and therapeutics
researchProduct

Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors

1998

Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and …

AdultMaleAdolescentFluvoxaminePharmacologyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesProspective cohort studyClozapineClozapinebusiness.industrySmokingMiddle AgedDrug interactionParoxetineParoxetinePsychiatry and Mental healthFluvoxamineSchizophreniaFemaleSerotoninbusinessReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Dose-dependent absorption and elimination of cefadroxil in man.

1991

The pharmacokinetic behaviour of cefadroxil was dose-dependent in healthy male volunteers following the oral administration of single doses of 5, 15, and 30 mg.kg-1. As the dose of cefadroxil increased from 5 to 15 and 30 mg.kg-1, the peak plasma concentrations, normalized to 5 mg.kg-1, decreased significantly from 15.1 to 10.7 and 7.6 mg.l-1, while the corresponding normalized areas under the plasma concentration-time curves from 0 to 2 h decreased significantly from 1258 to 946 and 801 min.mg.l-1. When the same subjects were given 5 mg.kg-1 of cefadroxil together with 45 mg.kg-1 of cephalexin, the absorption of cefadroxil was slowed to a similar or greater extent than with the high dose o…

AdultMaleAdolescentmedicine.drug_classMetabolic Clearance RateAntibioticsAbsorption (skin)PharmacologyKidneyAbsorptionPharmacokineticsOral administrationReference ValuesmedicineHumansPharmacology (medical)Drug InteractionsPharmacologyCephalexinDose-Response Relationship DrugChemistryCefadroxilKidney metabolismGeneral MedicineDrug interactionDose–response relationshipCefadroxilmedicine.drugEuropean journal of clinical pharmacology
researchProduct